GMAB
Genmab AS
NASDAQ: GMAB · HEALTHCARE · BIOTECHNOLOGY
$26.11
-2.54% today
Updated 2026-04-29
Market cap
$16.45B
P/E ratio
17.40
P/S ratio
4.42x
EPS (TTM)
$1.54
Dividend yield
—
52W range
$19 – $35
Volume
1.7M
Genmab AS (GMAB) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+23.7%
Last 4 quarters
Revenue YoY growth
-83.6%
Most recent quarter
EPS YoY growth
-75.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.7%
Last 3 reports
Positive reaction rate
0%
0 of 3 quarters
Largest single-day move
-2.9%
2026-02-17
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-17 | $0.21 | -43.2% | $30.03 | $29.16 | -2.9% |
| 2025-11-06 | $0.65 | +44.4% | $29.19 | $28.66 | -1.8% |
| 2025-08-07 | $0.54 | +58.8% | $21.51 | $21.43 | -0.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.37 | $0.21 | -43.2% | $1.05B | -83.6% |
| 2025-09-30 | $0.45 | $0.65 | +44.4% | $1.02B | -81.6% |
| 2025-06-30 | $0.34 | $0.54 | +58.8% | $5.86B | +652.5% |
| 2025-03-31 | $0.23 | $0.31 | +34.8% | $715.00M | +18.6% |
| 2024-12-31 | $0.28 | $0.84 | +200.0% | $6.44B | +37.7% |
| 2024-09-30 | $0.33 | $0.29 | -12.1% | $5.54B | +17.6% |
| 2024-06-30 | $0.32 | $0.32 | +0.0% | $779.00M | -81.3% |
| 2024-03-31 | $0.14 | $0.29 | +107.1% | $603.00M | — |
| 2023-12-31 | $0.30 | $0.14 | -53.3% | $4.68B | — |
| 2023-09-30 | $0.31 | $0.46 | +48.4% | $4.71B | — |
| 2023-06-30 | $0.29 | $0.30 | +3.4% | $4.17B | — |
Frequently asked questions
Has Genmab AS beaten earnings estimates?
Genmab AS has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +23.7% over the last 4 quarters.
How does GMAB stock react to earnings?
GMAB stock has moved an average of -1.7% in the trading day following earnings over its last 3 reports, with positive reactions in 0% of those quarters.
What is Genmab AS's revenue growth rate?
Genmab AS reported year-over-year revenue growth of -83.6% in its most recent quarter, with EPS growing -75.0% year-over-year.